论文部分内容阅读
用Ｉｏｄｏｇｅｎ法制备１２５Ｉ－ｒｈＩＬ－２。产品用ＳｅｐｈａｄｅｘＧ－５０凝胶过滤纯化。流出的组分用ＳＤＳ－ＰＡＧＥ测定纯度，选取放化纯度高于９５％的进行药代动力学研究。在ｉｖ剂量为５００，１０００及２５００ｎｇ／ｍｏｕｓｅ的１２５Ｉ－ｒｈＩＬ－２后，浓度－时间曲线按三房室模型拟合，其快分布相Ｔ１／２π约为３ｍｉｎ，慢分布相Ｔ１／２α约为８２ｍｉｎ，终末消除相Ｔ１／２β为７．５ｈ左右。ＡＵＣ与剂量呈较好的线性关系（ｒ＝０．９９９８）。ｉｍ１２５Ｉ－ｒｈＩＬ－２１０００ｎｇ／ｍｏｕｓｅ后浓度－时间曲线符合一室一级吸收，绝对生物利用度为０．５２，达峰浓度、时间分别为２３．０５ｎｇ／ｍｌ和１．９４ｈ。ｉｖ１５ｍｉｎ后，在肝脏中的浓度最高。２４ｈ内排出约７７％的标记药物。
125I-rhIL-2 was prepared by the Iodogen method. The product was purified by gel filtration on Sephadex G-50. The eluted fractions were assayed for purity by SDS-PAGE. Pharmacokinetic studies were performed with radiochemical purity greater than 95%. After iv doses of 500, 1000 and 2500 ng / mouse of 125I-rhIL-2, the concentration-time curves were fitted in a three-compartment model with a fast distribution phase T1 / 2π of approximately 3 min and a slow distribution phase T1 / 2α of approximately 82min, terminal elimination phase T1 / 2β is about 7.5h. AUC showed a good linear relationship with the dose (r = 0.9998). After im125I-rhIL-21000ng / mouse, the concentration-time curve was in accordance with the first-order absorption, the absolute bioavailability was 0.52 and the peak concentration was 23.05ng / ml and 1.94h respectively. After iv15min, the highest concentration in the liver. Approximately 77% of the labeled drug is discharged within 24 hours.